$VAR1 = undef;

Summary for peptidase M10.004: matrix metallopeptidase-9

Summary Gene structure Alignment Tree Sequences Sequence features Distribution Structure Literature Substrates Pharma

Names
MEROPS Name	matrix metallopeptidase-9
Other names	92 kDa gelatinase, gelatinase B, macrophage gelatinase, matrix metalloproteinase 9, MMP-9, MMP9, neutrophil gelatinase, type IV collagenase, type V collagenase

Domain architecture

MEROPS Classification
Classification	Clan MA >> Subclan MA(M) >> Family M10 >> Subfamily A >> M10.004
Holotype	matrix metallopeptidase-9 (Homo sapiens), Uniprot accession P14780 (peptidase unit: 105-458), MERNUM MER0001085
History	Identifier created: Handbook of Proteolytic Enzymes (1998) Academic Press, London.

Activity
Catalytic type	Metallo
Peplist	Included in the Peplist with identifier PL00157
NC-IUBMB	Subclass 3.4 (Peptidases) >> Sub-subclass 3.4.24 (Metalloendopeptidases) >> Peptidase 3.4.24.35
Enzymology	BRENDA database
Proteolytic events	CutDB database (184 cleavages)
Activity status	human: active (Bannikov et al., 2004) mouse: active (Masure et al., 1997)
Physiology	Role in turnover of extracellular matrix proteins.
Knockout	Knockout mice develop normally and are fertile (Itoh et al., 1999). They are resistant to a form of tail pathology that normally occurs in experimental auto-immune encephalomyelitis (Dubois et al., 1999), and have reduced lung damage in response to immunoglobulin G immune complexes (Warner et al., 2001). The deficient mice are however more susceptible to anti-glomerular basement membrane glomerulonephritis, and this is attributable to a role of gelatinase B in clearing deposits of fibrin from the glomeruli (Lelongt et al., 2001).
Pharmaceutical relevance	Drug target for prevention of pathological tissue damage. Work with knock-out mouse indicates that the enzyme plays a key role in the development of airway inflammation after allergen exposure (Cataldo et al., 2002), and may also be an attractive therapeutic target for limiting the effects of pathological arterial remodeling in restenosis and atherosclerosis (Galis et al., 2002). It is also suggested that adenovirus-mediated delivery of the gene in the antisense orientation has therapeutic potential for treating gliomas (Lakka et al., 2002).
Pathways	KEGG	Bladder cancer
	KEGG	Estrogen signaling pathway
	KEGG	Hepatitis B
	KEGG	Leukocyte transendothelial migration
	KEGG	MicroRNAs in cancer
	KEGG	Pathways in cancer
	KEGG	Proteoglycans in cancer
	KEGG	TNF signaling pathway
	KEGG	Transcriptional misregulation in cancer
Other databases	WIKIPEDIA	http://en.wikipedia.org/wiki/MMP9
Cleavage site specificity	Explanations of how to interpret the following cleavage site sequence logo and specificity matrix can be found here.
Cleavage pattern	g/pa/-/gl/-/g/- (based on 412 cleavages)

Specificity matrix

Amino acid	P4	P3	P2	P1	P1'	P2'	P3'	P4'
Gly	120	33	45	124	23	31	129	42
Pro	25	155	51	22	11	11	8	49
Ala	32	56	57	52	35	42	59	50
Val	28	29	18	21	42	26	24	19
Leu	38	32	34	35	107	41	18	38
Ile	13	13	9	6	30	14	10	10
Met	4	1	5	4	14	6	1	5
Phe	23	8	16	12	15	16	10	13
Tyr	2	3	13	10	15	6	4	6
Trp	0	0	0	1	2	5	2	1
Ser	20	23	31	19	31	26	39	35
Thr	10	10	12	13	6	33	18	15
Cys	1	1	4	2	0	3	4	2
Asn	11	4	3	17	3	9	7	12
Gln	12	6	23	9	23	32	9	8
Asp	7	5	4	7	6	8	10	24
Glu	12	5	16	15	8	17	12	23
Lys	14	8	25	20	21	32	17	21
Arg	16	5	36	13	14	40	22	13
His	8	8	6	10	2	11	4	3

Human genetics
Gene symbol	Locus	Megabases	Ensembl	Entrez gene	Gene Cards	OMIM
MMP9	20q11.2-q13.1		ENSG00000100985	4318	MMP9	120361
Mouse genetics
Gene symbol	Position	Megabases	Ensembl	Entrez gene	MGI
Mmp9	2:H1-H2		ENSMUSG00000017737	17395	MGI:97011